In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae
about
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.Ketolides in the treatment of respiratory infections.Dead bugs don't mutate: susceptibility issues in the emergence of bacterial resistance.Pharmacokinetics of antibacterial agents in the CSF of children and adolescents.The bioequivalence of telithromycin administered orally as crushed tablets versus tablets swallowed whole.
P2860
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647 (Telithromycin) against Chlamydia pneumoniae
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
In vitro pharmacodynamics of t ...... ) against Chlamydia pneumoniae
@en
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647
@nl
type
label
In vitro pharmacodynamics of t ...... ) against Chlamydia pneumoniae
@en
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647
@nl
prefLabel
In vitro pharmacodynamics of t ...... ) against Chlamydia pneumoniae
@en
In vitro pharmacodynamics of the new ketolides HMR 3004 and HMR 3647
@nl
P2093
P2860
P1476
In vitro pharmacodynamics of t ...... ) against Chlamydia pneumoniae
@en
P2093
P2860
P304
P356
10.1128/AAC.44.7.1846-1849.2000
P407
P577
2000-07-01T00:00:00Z